Abstract
GABA, acting via GABAA receptors, is well-accepted as the main inhibitory neurotransmitter of the mature brain, where it dampens neuronal excitability. The receptors properties have been studied extensively, yielding important information about its structure, pharmacology, and regulation that are summarized in this review. Several GABAergic drugs have been commonly used as anesthetics, sedatives, and anticonvulsants for decades. However, findings that GABA has critical functions in brain development, in particular during the late embryonic and neonatal period, raise worthwhile questions regarding the side effects of GABAergic drugs that may lead to long-term cognitive deficits. Here, we will review some of these drugs in parallel with the control of CNS development that GABA exerts via activation of GABAA receptors. This review aims to provide a basic science and clinical perspective on the function of GABA and related pharmaceuticals acting at GABAA receptors.
Keywords: GABA, anesthesia, epilepsy, neurogenesis, glutamate, proliferation, apoptosis, synaptic
CNS & Neurological Disorders - Drug Targets
Title: GABAA Receptors, Anesthetics and Anticonvulsants in Brain Development
Volume: 7 Issue: 2
Author(s): Oliver Henschel, Keith E. Gipson and Angelique Bordey
Affiliation:
Keywords: GABA, anesthesia, epilepsy, neurogenesis, glutamate, proliferation, apoptosis, synaptic
Abstract: GABA, acting via GABAA receptors, is well-accepted as the main inhibitory neurotransmitter of the mature brain, where it dampens neuronal excitability. The receptors properties have been studied extensively, yielding important information about its structure, pharmacology, and regulation that are summarized in this review. Several GABAergic drugs have been commonly used as anesthetics, sedatives, and anticonvulsants for decades. However, findings that GABA has critical functions in brain development, in particular during the late embryonic and neonatal period, raise worthwhile questions regarding the side effects of GABAergic drugs that may lead to long-term cognitive deficits. Here, we will review some of these drugs in parallel with the control of CNS development that GABA exerts via activation of GABAA receptors. This review aims to provide a basic science and clinical perspective on the function of GABA and related pharmaceuticals acting at GABAA receptors.
Export Options
About this article
Cite this article as:
Henschel Oliver, Gipson E. Keith and Bordey Angelique, GABAA Receptors, Anesthetics and Anticonvulsants in Brain Development, CNS & Neurological Disorders - Drug Targets 2008; 7 (2) . https://dx.doi.org/10.2174/187152708784083812
DOI https://dx.doi.org/10.2174/187152708784083812 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gamma-Decanolactone Improves Biochemical Parameters Associated with Pilocarpine-Induced Seizures in Male Mice
Current Molecular Pharmacology PET and SPECT Imaging of the NMDA Receptor System: An Overview of Radiotracer Development
Mini-Reviews in Medicinal Chemistry Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology TRPV1 Channel: A Potential Drug Target for Treating Epilepsy
Current Neuropharmacology Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging
Current Medicinal Chemistry Recent Progress in Transition-Metal-Catalyzed C-N Cross-Couplings: Emerging Approaches Towards Sustainability
Current Organic Synthesis A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry Magnolia officinalis Reduces Inflammation and Damage Induced by Recurrent Status Epilepticus in Immature Rats
Current Pharmaceutical Design Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and β-Catenin During Oxidative Stress
Current Neurovascular Research Drugs of Abuse and their Detection Methodologies: Contribution of Chemical Sensor
Current Organic Chemistry Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry Editorial [ Hot topic:Psychogenomics and Psychiatric Practice, a New Paradigm (Guest Editor: Tih-Shih Lee)]
Current Psychiatry Reviews Genetics and Molecular Biology of Tuberous Sclerosis Complex
Current Genomics Analysis of Functional Brain Images Using Population-Based Probabilistic Atlas
Current Medical Imaging Nicotine, Lung and Cancer
Anti-Cancer Agents in Medicinal Chemistry The NMDA Receptor NR2B Subunit: A Valid Therapeutic Target for Multiple CNS Pathologies
Current Medicinal Chemistry Preface
Current Neuropharmacology Neurological Disorders in Mice Lacking Glycogenes that are Mainly Expressed in Brain
CNS & Neurological Disorders - Drug Targets